Related Experiment Video
Updated: Jul 16, 2025
Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b
Published on: November 11, 2016
Discovery of potential novel TRPC5 inhibitors by virtual screening and bioassay
Meiling Shen1, Lingfeng Li2, Yue Li3
1State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650201, China; University of the Chinese Academy of Sciences, Beijing 100049, China.
Abstract:
The transient receptor potential canonical channel 5 (TRPC5), a member of the TRPC family, plays a crucial role in the regulation of various physiological activities and diseases, including those related to the central nervous system, cardiovascular system, kidney, and cancer. As a nonselective cation channel, TRPC5 mainly controls the influx of extracellular Ca2+ into cells, thereby modulating cellular depolarization and intracellular ion concentration. Inhibition of TRPC5 by small molecules presents a promising approach for the treatment of TRPC5-associated diseases. In this study, we conducted a comprehensive virtual screening of more than 1.5 million molecules from the Chemdiv database (https://www.chemdiv.com) to identify potential inhibitors of hTRPC5, utilizing the published structures and binding sites of hTRPC5 as a basis. Lipinski's rule, Veber's rule, PAINS filters, pharmacophore analysis, molecular docking, ADMET evaluation and cluster analysis methods were applied for the screening. From this rigorous screening process, 18 candidates exhibiting higher affinities to hTRPC5 were subsequently evaluated for their inhibitory effects on Ca2+ influx using a fluorescence-based assay. Notably, two molecules, namely SML-1 and SML-13, demonstrated significant inhibition of intracellular Ca2+ levels in hTRPC5-overexpressing HEK 293T cells, with IC50 values of 10.2 μM and 10.3 μM, respectively. These findings highlight SML-1 and SML-13 as potential lead molecules for the development of therapeutics targeting hTRPC5 and its associated physiological activities and diseases.
Insights
Researchers identified two novel small molecules, SML-1 and SML-13, that effectively inhibit the transient receptor potential canonical channel 5 (TRPC5). These compounds show promise for developing new TRPC5-targeting therapies for various diseases.
Area of Science:
- Pharmacology
- Molecular Biology
- Medicinal Chemistry
Background:
- Transient receptor potential canonical channel 5 (TRPC5) regulates physiological processes and is implicated in CNS, cardiovascular, kidney diseases, and cancer.
- TRPC5 functions as a nonselective cation channel, controlling Ca2+ influx and cellular ion balance.
- Inhibiting TRPC5 with small molecules offers a therapeutic strategy for TRPC5-related conditions.
Purpose of the Study:
- To identify novel small molecule inhibitors of human TRPC5 (hTRPC5) through virtual screening.
- To evaluate the inhibitory potential of identified compounds on hTRPC5-mediated calcium (Ca2+) influx.
- To discover lead compounds for the development of hTRPC5-targeted therapeutics.
Main Methods:
- Virtual screening of over 1.5 million compounds from the Chemdiv database against hTRPC5 structures.
- Application of Lipinski's rule, Veber's rule, PAINS filters, pharmacophore analysis, molecular docking, ADMET, and cluster analysis.
- In vitro evaluation of Ca2+ influx inhibition using a fluorescence-based assay in hTRPC5-overexpressing HEK 293T cells.
Main Results:
- Virtual screening identified 18 candidate molecules with high affinity for hTRPC5.
- Two compounds, SML-1 and SML-13, demonstrated significant inhibition of intracellular Ca2+ levels.
- SML-1 and SML-13 exhibited IC50 values of 10.2 μM and 10.3 μM, respectively, in hTRPC5-overexpressing cells.
Conclusions:
- SML-1 and SML-13 are potent inhibitors of hTRPC5-mediated Ca2+ influx.
- These compounds represent promising lead molecules for developing novel therapeutics targeting TRPC5.
- Further research into SML-1 and SML-13 could advance treatments for TRPC5-associated diseases.
More Related Videos
10:25Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology
Published on: November 22, 2024
10:07High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels
Published on: January 27, 2013
